NEW (2013) MESH HEADINGS WITH SCOPE NOTES (UNIT RECORD FORMAT; 10/16/2012) TOTAL 2013 NEW DESCRIPTORS = 302 MH - 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase UI - D063309 MN - D8.811.277.352.640.160.500 MN - D12.776.641.580.124 MS - A phosphodiesterase that specifically cleaves the 3'-phosphate linkage of 2',3'-cyclic nucleotides. It is found at high level in the cytoplasm of cells that form the MYELIN SHEATH. HN - 2013 BX - 2',3'-Cyclic Nucleotide 3'-Phosphodiesterases MH - Abdominoplasty UI - D061645 MN - E2.218.42 MN - E4.680.25 MS - Surgical removal of excess abdominal skin and fat and tightening of the ABDOMINAL WALL. Abdominoplasty may include LIPECTOMY of INTRA-ABDOMINAL FAT, tightening of the ABDOMINAL MUSCLES, and re-creation of the UMBILICUS. HN - 2013 MH - Acanthocheilonema UI - D063486 MN - B1.50.500.500.294.700.750.700.300.43 MS - A common genus of tropical filarial worms parasitic in humans and monkeys. AN - infection = ACANTHOCHEILONEMIASIS but infection with ACANTHOCHEILONEMA PERSTANS = ACANTHOCHEILONEMA PERSTANS INFECTION see MANSONELLIASIS; coordinate with specific helminth term (ANTIGENS, HELMINTH, etc) if pertinent HN - 2013; use Dipetalonema 1986-2012 MH - Acanthocheilonemiasis UI - D063485 MN - C3.335.508.700.750.361.137 MS - A tropical infectious disease found mainly in Africa that is caused by the filarial parasite ACANTHOCHEILONEMA PERSTANS. Symptoms include skin rashes, abdominal, chest, muscle, and joint pains, neurologic disorders, skin lumps, and elevated levels of white blood cells. The parasite is transmitted through the bite of small flies. AN - infection with ACANTHOCHEILONEMA PERSTANS = ACANTHOCHEILONEMIASIS PERSTANS INFECTION see MANSONELLIASIS HN - 2013 MH - Accelerometry UI - D061725 MN - E5.03 MS - Qualitative and quantitative measurement of MOVEMENT patterns. HN - 2013 MH - Acellular Dermis UI - D062088 MN - A17.815.180.40 MN - E7.945.750.40 MS - Remaining tissue from normal DERMIS tissue after the cells are removed. AN - coordinate with SKIN TRANSPLANTATION if appropriate HN - 2013 MH - Acid Sensing Ion Channel Blockers UI - D062646 MN - D27.505.519.562.750.100 MS - A subclass of sodium channel blockers that are specific for ACID-SENSING SODIUM CHANNELS. HN - 2013 BX - Proton-Gated Sodium Channel Blockers MH - Acid Sensing Ion Channels UI - D062565 MN - D12.776.157.530.400.875.50 MN - D12.776.543.550.425.875.50 MN - D12.776.543.585.400.875.50 MN - D12.776.641.24 MS - A family of proton-gated sodium channels that are primarily expressed in neuronal tissue. They are AMILORIDE-sensitive and are implicated in the signaling of a variety of neurological stimuli, most notably that of pain in response to acidic conditions. HN - 2013 BX - Proton-Gated Sodium Channels MH - Adenomyosis UI - D062788 MN - C13.351.500.852.113 MS - The extension of endometrial tissue (ENDOMETRIUM) into the MYOMETRIUM. It usually occurs in women in their reproductive years and may result in a diffusely enlarged uterus with ectopic and benign endometrial glands and stroma. HN - 2013; use ENDOMETRITIS 1975-2012 MH - Administration, Intravenous UI - D061605 MN - E2.319.267.82 MS - Delivery of substances through VENIPUNCTURE into the VEINS. HN - 2013 MH - Advanced Oxidation Protein Products UI - D062107 MN - D12.776.643.249 MS - A class of dityrosine-containing protein-derived molecules formed by OXIDATIVE STRESS. Their accumulation in plasma is associated with certain pathological conditions. HN - 2013 MH - Advanced Trauma Life Support Care UI - D061906 MN - E2.365.152 MN - E2.760.440.40 MN - N2.421.297.28 MN - N2.421.585.440.40 MS - The initial life support care of the severely injured patient. HN - 2013 BX - Advanced Trauma Life Support FX - Traumatology MH - Adventitia UI - D063194 MN - A10.165.189 MS - The outermost covering of organs, blood vessels, and other such structures in the body. HN - 2013; use CONNECTIVE TISSUE 2005-2012 MH - Ageism UI - D063506 MN - F1.145.813.550.249 MN - F1.145.813.629.500 MN - F1.829.595.249 MS - Biased behaviors or attitudes, differential treatment, unequal access to social participation or opportunities based on age. HN - 2013; use PREJUDICE 1995-2012 MH - Air Filters UI - D061808 MN - E5.196.454.201 MN - E7.39 MS - Barriers used to separate and remove PARTICULATE MATTER from air. HN - 2013 BX - Air Filter MH - Alice in Wonderland Syndrome UI - D062026 MN - C10.228.140.546.399.750.124 MN - C10.597.606.762.150 MN - C10.597.751.941.36 MN - C23.888.592.604.764.150 MN - C23.888.592.763.941.36 MN - F1.700.750.150 MS - Neurological condition characterized by disturbances in VISUAL PERCEPTION, most often of BODY SCHEMA, TIME PERCEPTION and HALLUCINATIONS. It is associated with MIGRAINE, infections (e.g., INFECTIOUS MONONUCLEOSIS), FEVER, EPILEPSY, and other neurological and psychiatric disorders. HN - 2013 MH - Aminobenzoates UI - D062365 MN - D2.241.223.100.50 MN - D2.455.426.559.389.127.20 MS - Derivatives of BENZOIC ACID that contain one or more amino groups attached to the benzene ring structure. Included under this heading are a broad variety of acid forms, salts, esters, and amides that include the aminobenzoate structure. HN - 2013 MH - Anatomic Variation UI - D063405 MN - H1.158.100.45 MS - Peculiarities associated with the internal structure, form, topology, or architecture of organisms that distinguishes them from others of the same species or group. HN - 2013 MH - Animal Distribution UI - D063147 MN - F1.145.113.69 MN - G16.49 MS - A process by which animals in various forms and stages of development are physically distributed through time and space. HN - 2013 BX - Animal Dispersal MH - Antioxidant Response Elements UI - D061745 MN - G2.111.570.80.689.675.700.40 MN - G5.360.80.689.675.700.40 MN - G5.360.340.24.340.137.750.680.765.40 MS - Nucleotide sequences that are found in the PROMOTER REGIONS of the genes of stress-responsive and cytoprotective proteins, such as those encoding antioxidant and PHASE II DETOXIFICATION enzymes. NF-E2-RELATED FACTOR 2 containing transcription factors bind to these elements during induction of these genes. HN - 2013 FX - Metabolic Detoxication, Phase II FX - NF-E2-Related Factor 2 MH - Arterial Pressure UI - D062186 MN - G9.330.380.76.347 MS - The blood pressure in the ARTERIES. It is commonly measured with a SPHYGMOMANOMETER on the upper arm which represents the arterial pressure in the BRACHIAL ARTERY. HN - 2013 MH - Atrial Pressure UI - D062185 MN - G9.330.190.75.600 MN - G9.330.380.37 MS - The pressure within the CARDIAC ATRIUM. It can be measured directly by using a pressure catheter (see HEART CATHETERIZATION). It can be also estimated using various imaging techniques or other pressure readings such as PULMONARY CAPILLARY WEDGE PRESSURE (an estimate of left atrial pressure) and CENTRAL VENOUS PRESSURE (an estimate of right atrial pressure). HN - 2013 MH - AU Rich Elements UI - D063307 MN - G2.111.570.80.689.687.61 MN - G5.360.80.689.687.61 MN - G5.360.340.24.220.880.880.500 MN - G5.360.340.24.340.137.910.880.500 MS - RNA sequences composed of ADENINE NUCLEOTIDES and URACIL NUCLEOTIDES, that are located in the 3'UNTRANSLATED REGIONS of MESSENGER RNA molecules that are rapidly degraded. They are also known as AREs. HN - 2013 MH - Balkan Peninsula UI - D063368 MN - Z1.542.101 MS - A peninsula in Southeast EUROPE between the Adriatic and Ionian seas on the West and Aegean and Black Seas on the East. (from www.merriam-webster.com/dictionary/balkan%20peninsula) HN - 2013 MH - Balloon Embolectomy UI - D063125 MN - E2.148.93 MN - E4.100.814.445.500 MS - The use of balloon CATHETERS to remove emboli by retraction of the balloon that is inflated behind the EMBOLUS. HN - 2013 BX - Fogarty Balloon Catheterization MH - Balloon Valvuloplasty UI - D063126 MN - E2.148.108 MS - Widening of a stenosed HEART VALVE by the insertion of a balloon CATHETER into the valve and inflation of the balloon. HN - 2013 BX - Balloon Valvotomy MH - Binge Drinking UI - D063425 MN - C25.100.437 MN - F1.145.317.269.500 MN - F3.900.100.550 MS - Drinking an excessive amount of ALCOHOLIC BEVERAGES in a short period of time. HN - 2013 MH - Bioprinting UI - D062028 MN - E5.111 MN - J1.293.69.124 MS - A material transfer technique used for assembling biological material or cells into a prescribed organization to create functional structures such as MICROCHIP ANALYTICAL DEVICES, cell microarrays, or three dimensional anatomical structures. HN - 2013 FX - Guided Tissue Regeneration MH - Biopsy, Large-Core Needle UI - D062005 MN - E1.370.225.500.384.100.119.750 MN - E1.370.225.998.54.119.750 MN - E1.370.388.100.100.750 MN - E4.74.119.750 MN - E4.665.100.750 MN - E5.200.500.384.100.119.750 MN - E5.200.998.54.119.750 MN - E5.242.384.100.119.750 MS - The use of needles usually larger than 14-gauge to remove tissue samples large enough to retain cellular architecture for pathology examination. AN - usually NIM with specific organ/pathol (IM) + disease /pathol (IM) HN - 2013 MH - Brain-Computer Interfaces UI - D062207 MN - E7.305.76 MS - Instrumentation consisting of hardware and software that communicates with the BRAIN. The hardware component of the interface records brain signals, while the software component analyzes the signals and converts them into a command that controls a device or sends a feedback signal to the brain. HN - 2013 FX - User-Computer Interface MH - Breakfast UI - D062408 MN - F1.145.407.432.500.100 MN - F1.145.466.349.500.100 MN - J2.500.590.120 MS - The first meal of the day. HN - 2013 MH - Breath Holding UI - D062485 MN - G9.772.770.755.349 MS - An involuntary or voluntary pause in breathing, sometimes accompanied by loss of consciousness. HN - 2013 MH - Brown Recluse Spider UI - D063287 MN - B1.50.500.131.166.803.600 MS - A spider of the genus Loxosceles, found in the midwestern and other parts of the United States, which carries a hemolytic venom that produces local necrosis or ulceration. AN - bite: coordinate IM with ARACHNIDISM (IM) HN - 2013 MH - Buschke-Lowenstein Tumor UI - D062688 MN - C2.256.650.810.217.500 MN - C2.800.801.220.500 MN - C2.825.810.110.500 MN - C2.928.914.217.500 MN - C4.557.470.200.450.500 MN - C4.557.470.700.450.500 MN - C17.800.838.790.810.110.500 MS - Exophytic tumor of the anogenital region associated with HPV infections. It becomes a large cauliflower-like, hyperkeratotic, verrucous mass that is locally destructive with little atypical cells. Histologically, tumor cells are broad rete peg structures that tend to invade deeper than CONDYLOMATA ACUMINATA. AN - coordinate IM with precoordinated organ/neoplasm term (IM) HN - 2013 BX - Buschke-Löwenstein Tumor MH - Cannabinoid Receptor Agonists UI - D063386 MN - D27.505.519.625.85.500 MN - D27.505.696.399.472.188.500 MS - Compounds that interact with and stimulate the activity of CANNABINOID RECEPTORS. HN - 2013 FX - Cannabinoids FX - Endocannabinoids FX - Receptors, Cannabinoid MH - Cannabinoid Receptor Antagonists UI - D063387 MN - D27.505.519.625.85.750 MN - D27.505.696.399.472.188.750 MS - Compounds that inhibit or block the activity of CANNABINOID RECEPTORS. HN - 2013 MH - Cannabinoid Receptor Modulators UI - D063385 MN - D27.505.519.625.85 MN - D27.505.696.399.472.188 MS - Compounds that interact with and modulate the activity of CANNABINOID RECEPTORS. HN - 2013 MH - Carbonated Water UI - D061545 MN - D1.455.900.600.500 MN - D1.650.550.925.600.500 MN - J2.200.300.500 MN - J2.200.418.500 MS - Water naturally or artificially infused with CARBON DIOXIDE. HN - 2013 MH - Cardiac Catheters UI - D062906 MN - E7.132.750.249 MS - Catheters inserted into various locations within the heart for diagnostic or therapeutic purposes. HN - 2013 FX - Cardiac Catheterization MH - Caspase Inhibitors UI - D061945 MN - D27.505.519.389.745.325.500 MS - Endogenous and exogenous compounds and that either inhibit CASPASES or prevent their activation. HN - 2013 MH - Catheter Obstruction UI - D061807 MN - E5.325.95 MN - E7.132.249 MS - A hindrance to the passage of fluids through a CATHETER. AN - coordinate with specific type of catheterization HN - 2013 FX - Catheter-Related Infections MH - Cell Surface Display Techniques UI - D061505 MN - E5.393.220.250.500 MN - E5.393.420.601.292 MS - Techniques utilizing cells that express RECOMBINANT FUSION PROTEINS engineered to translocate through the CELL MEMBRANE and remain attached to the outside of the cell. HN - 2013 FX - Peptide Library MH - Central Pattern Generators UI - D063226 MN - A8.511.500 MS - Networks of nerve cells that control the firing patterns of MOTOR NEURONS to produce rhythmic movements such as MASTICATION; WALKING; SWIMMING; RESPIRATION; and PERISTALSIS. HN - 2013 BX - Central Pattern Generator Neurons MH - Central Venous Catheters UI - D062905 MN - E7.132.750.500 MS - Catheters that are inserted into a large central vein such as a SUBCLAVIAN VEIN or FEMORAL VEIN. HN - 2013 FX - Catheterization, Central Venous MH - Chemical Safety UI - D062067 MN - N6.850.135.60.75.199 MS - Risk or hazard associated with the handling and use of chemicals. HN - 2013 MH - Chloroacetates UI - D062845 MN - D2.241.81.18.214 MN - D2.455.526.439.196 MS - ACETIC ACID or acetic acid esters substituted with one or more CHLORINE atoms. HN - 2013 MH - Chromophore-Assisted Light Inactivation UI - D061885 MN - E5.198 MS - A technique for causing a targeted loss of molecular function from REACTIVE OXYGEN SPECIES that are formed by the illumination of dyes placed in the immediate vicinity of the target molecule. HN - 2013 MH - Claudin-1 UI - D062445 MN - D12.776.543.984.200.100 MS - An integral membrane protein that is localized to TIGHT JUNCTIONS, where it plays a role in controlling the paracellular permeability of polarized cells. Mutations in the gene for claudin-1 are associated with Neonatal Ichthyosis-Sclerosing Cholangitis (NISCH) Syndrome. HN - 2013 MH - Claudin-2 UI - D062446 MN - D12.776.543.984.200.200 MS - A claudin subtype that is associated with the formation of cation-selective channels and increased epithelial permeability. It is localized to the TIGHT JUNCTIONS of the PROXIMAL KIDNEY TUBULE and INTESTINAL EPITHELIUM. HN - 2013 MH - Claudin-3 UI - D062465 MN - D12.776.543.984.200.300 MS - A ubiquitously-expressed claudin subtype that acts as a general barrier-forming protein in TIGHT JUNCTIONS. Elevated expression of claudin-3 is found in a variety of tumor cell types, suggesting its role as a therapeutic target for specific ANTINEOPLASTIC AGENTS. HN - 2013 MH - Claudin-4 UI - D062506 MN - D12.776.543.984.200.400 MS - A claudin subtype that takes part in maintaining the barrier-forming property of TIGHT JUNCTIONS. Claudin-4 is found associated with CLAUDIN-8 in the KIDNEY COLLECTING DUCT where it may play a role in paracellular chloride ion reabsorption. HN - 2013 BX - Claudin4 MH - Claudin-5 UI - D062507 MN - D12.776.543.984.200.500 MS - A claudin subtype that is found localized to TIGHT JUNCTIONS in VASCULAR ENDOTHELIAL CELLS. The protein was initially identified as one of several proteins which are deleted in VELOCARDIOFACIAL SYNDROME and may play an important role in maintaining the integrity of the BLOOD-BRAIN BARRIER. HN - 2013 FX - DiGeorge Syndrome MH - Community Integration UI - D062309 MN - I1.880.787.354 MS - Policies and programs which ensure that DISPLACED PERSONS and chronic illnesses receive the support and SOCIAL SERVICES needed to live in their communities. HN - 2013 MH - Connectome UI - D063132 MN - E1.370.350.578.875.500.249 MN - E1.370.376.537.625.500.249 MS - A comprehensive map of the physical interconnections of an organism's neural networks. This modular organization of neuronal architecture is believed to underlie disease mechanisms and the biological development of the CENTRAL NERVOUS SYSTEM. HN - 2013 BX - Brain Connectomics BX - Connectome Mapping BX - Connectomics MH - Controlled Substances UI - D061891 MN - D26.49 MS - Drugs or chemical agents whose manufacture, possession, or use are regulated by government. This may include narcotics and prescription medications. HN - 2013 MH - Conversion to Open Surgery UI - D061887 MN - E4.800.250.155 MS - Changing an operative procedure from an endoscopic surgical procedure to an open approach during the INTRAOPERATIVE PERIOD. HN - 2013 MH - Corneal Pachymetry UI - D063171 MN - E1.370.380.112 MS - Measurement of the thickness of the CORNEA. HN - 2013 MH - Coxsackie and Adenovirus Receptor-Like Membrane Protein UI - D062727 MN - D12.776.395.550.200.537.500 MN - D12.776.543.550.200.537.500 MN - D12.776.543.750.925.124 MN - D12.776.543.984.600.500 MN - D23.50.301.350.537.500 MS - An Ig superfamily transmembrane protein that localizes to junctional complexes that occur between ENDOTHELIAL CELLS and EPTHELIAL CELLS. The protein may play a role in cell-cell adhesion and is the primary site for the attachment of ADENOVIRUSES during infection. HN - 2013 MH - Craniospinal Irradiation UI - D061888 MN - E2.815.230 MS - A comprehensive radiation treatment of the entire CENTRAL NERVOUS SYSTEM. HN - 2013 MH - Crowdsourcing UI - D063045 MN - L1.280.179 MS - Social media model for enabling public involvement and recruitment in participation. Use of social media to collect feedback and recruit volunteer subjects. HN - 2013 MH - Cyclic GMP-Dependent Protein Kinase Type I UI - D062965 MN - D8.811.913.696.620.682.700.150.150.500 MN - D12.644.360.200.150.500 MN - D12.776.476.200.150.500 MS - A cyclic GMP-dependent protein kinase subtype that is expressed in SMOOTH MUSCLE tissues and plays a role in regulation of smooth muscle contraction. Two isoforms, PKGIalpha and PKGIbeta, of the type I protein kinase exist due to alternative splicing of its mRNA. HN - 2013 MH - Cyclic GMP-Dependent Protein Kinase Type II UI - D062967 MN - D8.811.913.696.620.682.700.150.150.750 MN - D12.644.360.200.150.750 MN - D12.776.476.200.150.750 MS - A cyclic GMP-dependent protein kinase subtype that is expressed predominantly in INTESTINES, BRAIN, and KIDNEY. The protein is myristoylated on its N-terminus which may play a role its membrane localization. HN - 2013 MH - Cycloaddition Reaction UI - D061565 MN - E5.916.39.406 MN - G2.607.750.155.374 MN - J1.897.836.249.374 MS - Synthetic organic reactions that use reactions between unsaturated molecules to form cyclical products. HN - 2013 BX - Cycloaddition MH - Cystadenofibroma UI - D062625 MN - C4.557.450.565.590.595.50.500 MN - C4.557.470.590.482 MN - C4.557.470.625.50.500 MS - Benign or borderline malignant neoplasm of the ovary and surrounding tissues. It is characterized by tumor(s) with cystic glands which are lined by cuboidal EPITHELIAL CELLS with clear cytoplasm, resembling ENDOMETRIUM cells. The glands are separated by fibroblastic STROMAL CELLS. AN - coordinate IM with probably OVARIAN NEOPLASMS (IM) HN - 2013 FX - Adenocarcinoma, Clear Cell MH - Databases, Chemical UI - D062126 MN - L1.470.750.750.300 MN - L1.700.508.300.188.400.300 MS - Databases devoted to knowledge about specific chemicals. HN - 2013 BX - Databases, Molecular MH - Databases, Pharmaceutical UI - D062313 MN - L1.470.750.750.400 MN - L1.700.508.300.188.400.400 MS - Databases devoted to knowledge about PHARMACEUTICAL PRODUCTS. HN - 2013 BX - Databases, Drug FX - Dictionaries, Pharmaceutic MH - Degenerin Sodium Channels UI - D062626 MN - D12.776.157.530.400.875.100 MN - D12.776.543.550.425.875.100 MN - D12.776.543.585.400.875.100 MS - A family of mechanosensitive sodium channels found primarily in NEMATODES where they play a role in CELLULAR MECHANOTRANSDUCTION. Degenerin sodium channels are structurally-related to EPITHELIAL SODIUM CHANNELS and are named after the fact that loss of their activity results in cellular degeneration. HN - 2013 BX - Degenerin Ion Channels MH - Dentofacial Deformities UI - D063169 MN - C5.660.207.540.229 MN - C7.650.500.229 MN - C16.131.621.207.540.315 MN - C16.131.850.500.229 MS - An abnormality of the jaws or teeth affecting the contour of the face. Such abnormality could be acquired or congenital. HN - 2013 MH - Dermatologic Surgical Procedures UI - D062109 MN - E4.680.275 MS - Operative procedures performed on the SKIN. HN - 2013 FX - Cosmetic Techniques FX - Surgery, Plastic MH - Dimensional Measurement Accuracy UI - D061827 MN - E5.318.780.725.500 MN - E5.337.851.500 MN - N5.715.360.780.685.500 MN - N6.850.520.445.725.500 MS - The closeness of a determined value of a physical dimension to the actual value. HN - 2013 MH - Diuretics, Potassium Sparing UI - D062865 MN - D27.505.696.560.500.726 MS - A subclass of diuretics that limits the secretion of POTASSIUM into the URINE. HN - 2013; use SODIUM CHANNEL BLOCKERS 2002-2012 BX - Potassium Sparing Diuretics MH - Drug Overdose UI - D062787 MN - C25.341 MN - C25.723.276.531 MN - E2.319.754.500 MS - Accidental or deliberate use of a medication or street drug in excess of normal dosage. HN - 2013 MH - Dual MEDICAID MEDICARE Eligibility UI - D063026 MN - N3.109 MS - Coordination of coverage eligibility of those individuals who are entitled to MEDICAID and MEDICARE. HN - 2013 MH - Electronic Nose UI - D062609 MN - E7.230.210 MN - E7.305.296 MS - A device that detects odors or flavors. HN - 2013 MH - Endocannabinoids UI - D063388 MN - D10.251.265 MS - Fatty acid derivatives that have specificity for CANNABINOID RECEPTORS. They are structurally distinct from CANNABINOIDS and were originally discovered as a group of endogenous CANNABINOID RECEPTOR AGONISTS. HN - 2013(2004) MH - Endoreduplication UI - D062951 MN - G5.355.200.820 MS - A type of nuclear polyploidization in which multiple cycles of DNA REPLICATION occur in the absence of CELL DIVISION and result in a POLYPLOID CELL. HN - 2013 FX - Polytene Chromosomes MH - Endoscopic Ultrasound-Guided Fine Needle Aspiration UI - D061765 MN - E1.370.225.500.384.100.119.500.500 MN - E1.370.225.500.384.100.370.500 MN - E1.370.225.998.54.119.500.500 MN - E1.370.225.998.54.370.500 MN - E1.370.350.850.855.500 MN - E1.370.388.100.100.500.500 MN - E1.370.388.100.370.500 MN - E4.74.119.500.500 MN - E4.74.370.500 MN - E4.800.890.500 MN - E5.200.500.384.100.119.500.500 MN - E5.200.500.384.100.370.500 MN - E5.200.998.54.119.500.500 MN - E5.200.998.54.370.500 MN - E5.242.384.100.119.500.500 MN - E5.242.384.100.370.500 MS - Conducting a fine needle biopsy with the aid of ENDOSCOPIC ULTRASONOGRAPHY. HN - 2013 MH - Epidemiological Monitoring UI - D062665 MN - E5.318.375 MN - N6.850.520.460 MS - Collection, analysis, and interpretation of data about the frequency, distribution, and consequences of disease or health conditions, for use in the planning, implementing, and evaluating public health programs. AN - do not confuse with ENVIRONMENTAL MONITORING HN - 2013 (1986) MH - Epigenetic Repression UI - D063185 MN - G5.355.315.203.311 MS - The turning off of GENETIC TRANSCRIPTION in certain regions of CHROMATIN without changes in the DNA sequence. Typically epigenetic repression is a way that developmental changes are programmed at the cellular level. HN - 2013 MH - Epithelial Sodium Channel Agonists UI - D062708 MN - D27.505.519.562.625.249 MS - Compounds that either stimulate the opening or prevent closure of EPITHELIAL SODIUM ION CHANNELS. HN - 2013 MH - Epithelial Sodium Channel Blockers UI - D062686 MN - D27.505.519.562.750.374 MN - D27.505.696.560.500.726.100 MS - A subclass of sodium channel blockers that are specific for EPITHELIAL SODIUM CHANNELS. HN - 2013 BX - Epithelial Sodium Ion Channel Blockers MH - Estuaries UI - D063366 MN - G1.311.625.540 MS - A partially enclosed body of water, and its surrounding coastal habitats, where saltwater from the ocean mixes with fresh water from rivers or streams. The resulting mixture of seawater and fresh water is called brackish water and its salinity can range from 0.5 to 35 ppt. (accessed http://oceanservice.noaa.gov/education/kits/estuaries/estuaries01_whatis.html) HN - 2013 MH - Exosome Multienzyme Ribonuclease Complex UI - D063326 MN - D5.500.562.405 MN - D8.811.277.352.700.687 MN - D8.811.600.283 MS - An intracellular ribonucleolytic protein complex that participates in POSTRANSCRIPTIONAL RNA PROCESSING and RNA DEGRADATION. AN - do not confuse with EXOSOMES HN - 2013 FX - Exosomes MH - External Debt UI - D061895 MN - N3.219.416 MS - Money owed to creditors outside of a country. HN - 2013 MH - Fibrin Clot Lysis Time UI - D063285 MN - E1.370.225.625.265 MN - E5.200.625.265 MN - G9.188.315 MS - A measurement of the time needed for FIBRINOLYSIS to occur. HN - 2013 FX - Fibrinolysis MH - Field Hospitals UI - D062208 MN - N2.278.421.473.500 MS - Mobile, self-contained, self-sufficient health care facilities capable of rapid deployment and expansion or contraction to meet immediate emergency requirements for a specified period of time. HN - 2013 MH - Food Assistance UI - D063105 MN - I1.880.787.839.500 MN - N3.219.521.346.506.281 MS - Food or financial assistance for food given to those in need. AN - do not confuse with FOOD SERVICES HN - 2013 MH - Food Quality UI - D063427 MN - J1.576.423.850.730 MN - N6.850.601 MS - Ratings of the characteristics of food including flavor, appearance, nutritional content, and the amount of microbial and chemical contamination. HN - 2013 FX - Food Analysis FX - Food Handling FX - Food Labeling MH - Foot Orthoses UI - D061826 MN - E7.858.442.743.659 MS - Devices used to support or align the foot structure, or to prevent or correct foot deformities. HN - 2013 MH - Fukushima Nuclear Accident UI - D062406 MN - K1.400.504.984.186 MN - N6.850.135.848.750 MS - Nuclear power accident that occurred following the Tohoku-Kanto earthquake of March 11, 2011 in the northern region of Japan. HN - 2013 MH - Fungal Capsules UI - D062607 MN - A19.530 MS - An extracellular layer outside the cell wall of a fungus composed of polysaccharides. It may serve a protective role amongst others. HN - 2013 MH - Fungal Polysaccharides UI - D062610 MN - D9.698.357 MN - D23.50.202.283 MS - Cell wall components constituting a polysaccharide core found in fungi. They may act as antigens or structural substrates. HN - 2013 MH - Genioplasty UI - D063172 MN - E6.645.562.249 MS - A surgical procedure done largely for cosmetic reasons to correct receding chins, chin misalignment, or chin excess. HN - 2013 MH - Genocide UI - D063365 MN - I1.198.240.903.149 MN - I1.880.735.944.903.149 MS - The deliberate annihilation of a national, ethnic, or religious group, in part or in whole. HN - 2013; use Homocide 2000-2012 MH - Geographic Mapping UI - D062305 MN - E5.318.389 MN - E5.318.740.933.249 MN - N5.715.360.750.746.249 MN - N6.850.520.830.933.249 MS - Creating a representation of areas of the earth or other celestial bodies, for the purpose of visualizing spatial distributions of various information. HN - 2013 FX - Geographic Information Systems FX - Maps as Topic FX - Topography, Medical MH - Geography, Medical UI - D062306 MN - H1.277.500.97 MN - H2.403.352 MS - The area of medicine concerned with the effects on health and disease due to geographic factors such as CLIMATE, environmental conditions, and geographic location. AN - IM as the discipline (education, history, etc); NIM with no qualifiers as a coordinate HN - 2013 BX - Medical Geography MH - Hand Hygiene UI - D063373 MN - N6.850.780.200.412 MS - Practices involved in preventing the transmission of diseases by hand. HN - 2013 MH - Health Impact Assessment UI - D062489 MN - E5.318.308.237 MN - N3.349.380.210.500 MS - Combination of procedures, methods, and tools by which a policy, program, or project may be judged as to its potential effects on the health of a population, and the distribution of those effects within the population. HN - 2013 MH - Health Information Management UI - D063025 MN - L1.399.500 MS - Management of the acquisition, organization, retrieval, and dissemination of health information. HN - 2013 MH - Health Information Systems UI - D063005 MN - L1.700.508.300.361 MS - A system for the collection and/or processing of data from various sources, and using the information for policy making and management of health services. It could be paper-based or electronic. (From http://web.worldbank.org/WBSITE/EXTERNAL/TOPICS/EXTHEALTHNUTRITIONANDPOPULATION/EXTHSD/0,,contentMDK:22239824~menuPK:376799~pagePK:148956~piPK:216618~theSitePK:376793,00.html. http://www.who.int/healthinfo/systems/en/) HN - 2013 MH - Health Insurance Exchanges UI - D062265 MN - N3.219.521.576.343.918.500 MS - State-provided health insurance marketplaces established under the PATIENT PROTECTION AND AFFORDABLE CARE ACT. HN - 2013 MH - Health Services for Transgendered Persons UI - D062985 MN - N2.421.325 MS - Access to specialized care for transgendered populations. Health systems organized to take account of the special healthcare needs of marginalized groups who may face barriers in accessing health services. (http://www.who.int/reproductivehealth/topics/linkages/guidance_package.pdf) HN - 2013 FX - Transgendered Persons MH - Healthcare Financing UI - D061889 MN - N3.219.483.359 MS - Methods of generating, allocating, and using financial resources in healthcare systems. HN - 2013 BX - Health Financing MH - Heavy Ion Radiotherapy UI - D063193 MN - E2.815.250 MS - The use of a heavy ion particle beam for radiotherapy, such as the HEAVY IONS of CARBON. HN - 2013 MH - Hemiarthroplasty UI - D062785 MN - E4.555.110.110.482 MN - E4.650.110.482 MS - A partial joint replacement in which only one surface of the joint is replaced with a PROSTHESIS. HN - 2013 MH - Hemorrhoidectomy UI - D061865 MN - E4.210.526 MS - The surgical removal of HEMORRHOIDS. HN - 2013 MH - Homophobia UI - D063509 MN - F1.145.813.550.374 MN - F1.145.813.629.562 MN - F1.829.595.374 MS - Differential treatment or unequal access to opportunities or services based on perceived homosexual preference or orientation. HN - 2013 MH - Hospitals, High-Volume UI - D061847 MN - N2.278.421.414 MS - Hospitals with a much higher than average utilization by physicians and a large number of procedures. HN - 2013 MH - Hospitals, Low-Volume UI - D061846 MN - N2.278.421.434 MS - Hospitals with a much lower than average utilization by physicians and smaller number of procedures. HN - 2013 BX - Low-Volume Hospitals MH - Human Migration UI - D063426 MN - I1.240.600.525 MN - N1.224.625.525 MN - N6.850.505.400.700.525 MS - Periodic movement of human settlement from one geographical location to another. AN - migration of ancient populations goes here; ANIMAL MIGRATION is available for animals HN - 2013 MH - Human Papillomavirus DNA Tests UI - D061809 MN - E1.370.225.880.500 MN - E5.200.880.500 MN - E5.393.462 MN - E5.393.520.750 MS - Methods for detecting or typing the DNA of an ALPHAPAPILLOMAVIRUS in biological tissues and fluids. HN - 2013 FX - DNA Probes, HPV MH - Hydrology UI - D062070 MN - H1.158.273.248.875 MN - H1.277.249.875 MN - J1.293.622 MS - Science dealing with the properties, distribution, and circulation of water on and below the earth's surface, and atmosphere. AN - IM as the discipline (education, history, etc) only; NIM with no qualifiers as a coordinate HN - 2013 FX - Limnology MH - Hydroxybenzoate Ethers UI - D062425 MN - D2.241.223.100.300.350 MN - D2.241.511.390.350 MN - D2.355.726.675 MN - D2.455.426.559.389.127.281.350 MN - D2.455.426.559.389.657.654.638 MS - Benzoate derivatives that contain one or more alkyl or aryl groups linked to the benzene ring structure by OXYGEN. HN - 2013 MH - Hydroxybenzoates UI - D062385 MN - D2.241.223.100.300 MN - D2.241.511.390 MN - D2.455.426.559.389.127.281 MN - D2.455.426.559.389.657.410 MS - Benzoate derivatives substituted by one or more hydroxy groups in any position on the benzene ring. HN - 2013 MH - Image-Guided Biopsy UI - D061705 MN - E1.370.225.500.384.100.370 MN - E1.370.225.998.54.370 MN - E1.370.388.100.370 MN - E4.74.370 MN - E5.200.500.384.100.370 MN - E5.200.998.54.370 MN - E5.242.384.100.370 MS - Conducting a biopsy procedure with the aid of a MEDICAL IMAGING modality. AN - usually NIM with specific organ/pathol (IM) + disease /pathol (IM) HN - 2013 FX - Surgery, Computer-Assisted MH - Immobilized Nucleic Acids UI - D061925 MN - D13.444.404 MS - DNA or RNA bound to a substrate thereby having fixed positions. HN - 2013 MH - Immunoreceptor Tyrosine-Based Activation Motif UI - D061625 MN - G2.111.570.60.40.750 MN - G2.111.570.790.709.600.40.440 MS - A conserved AMINO ACID SEQUENCE located in the intracellular domains of a family of transmembrane proteins involved in various IMMUNE RESPONSES. The CONSENSUS SEQUENCE of this motif is YXXL(or I)X(6-8)YXXL(or I) (where X denotes any amino acid). When phosphorylated ITAM motifs provide docking sites for PROTEIN TYROSINE KINASES of the Syk family thus forming signaling complexes which lead to activation of immune responses. HN - 2013 MH - Immunoreceptor Tyrosine-Based Inhibition Motif UI - D061626 MN - G2.111.570.60.40.875 MN - G2.111.570.790.709.600.40.480 MS - A conserved AMINO ACID SEQUENCE located in the intracellular domains of a family of transmembrane proteins that negatively regulate the signal transduction processes emanating from transmembrane proteins containing IMMUNORECEPTOR TYROSINE-BASED ACTIVATION MOTIFS. The CONSENSUS SEQUENCE of this motif is I(or V)LXYXXL(or V) (where X denotes any amino acid). Also known as ITIM motifs. HN - 2013 MH - Infant, Extremely Premature UI - D062071 MN - M1.60.703.520.520.500 MS - A human infant born before 28 weeks of GESTATION. AN - check the tag INFANT, NEWBORN HN - 2013 FX - Infant, Extremely Low Birth Weight FX - Premature Birth MH - Intense Pulsed Light Therapy UI - D062325 MN - E2.774.465 MS - Treatment of the skin with flashlamps of prescribed wavelengths, fluence, and pulse durations which target specific chromophores to induce photothermolysis at specific locations in the skin such as at the HAIR FOLLICLE or SPIDER VEINS. AN - coordinate with specific skin disease /ther and/or cosmetic technique; use PHOTOCHEMOTHERAPY for intense pulsed light used with PHOTOSENSITIZING AGENTS and do not index here HN - 2013 FX - Lasers, Dye MH - Inventions UI - D062069 MN - J1.897.400 MS - A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model. HN - 2013 FX - Intellectual Property FX - Patents MH - Inventors UI - D062068 MN - M1.526.493 MS - Persons or entities that introduce a novel composition, device, or process, as well as improvements thereof. HN - 2013 MH - Islands UI - D062312 MN - G16.500.275.505 MN - N6.230.295 MN - Z1.639 MS - Tracts of land completely surrounded by water. AN - general or unspecified; prefer specifics HN - 2013 MH - Junctional Adhesion Molecule A UI - D062745 MN - D12.776.395.550.200.537.750 MN - D12.776.543.550.200.537.750 MN - D12.776.543.750.53 MN - D12.776.543.984.600.700 MN - D23.50.301.264.35.456 MN - D23.50.301.350.537.750 MN - D23.101.100.110.456 MS - A cell adhesion protein that is found within TIGHT JUNCTIONS of ENDOTHELIAL CELLS and on the CELL MEMBRANE surface of circulating PLATELETS. HN - 2013 MH - Junctional Adhesion Molecule B UI - D062765 MN - D12.776.395.550.200.537.875 MN - D12.776.543.550.200.537.875 MN - D12.776.543.984.600.800 MN - D23.50.301.264.35.474 MN - D23.50.301.350.537.875 MN - D23.101.100.110.474 MS - A junctional adhesion molecule subtype that is localized to high endothelial VENULES, heart ENDOTHELIUM, TROPHOBLASTS of the PLANCENTA, and in the ENDOTHELIUM of ARTERIOLES. HN - 2013 MH - Junctional Adhesion Molecule C UI - D062786 MN - D12.776.395.550.200.537.937 MN - D12.776.543.550.200.537.937 MN - D12.776.543.984.600.900 MN - D23.50.301.350.537.937 MS - A junctional adhesion molecule subtype that is expressed at high levels in PLACENTA; BRAIN; KIDNEY; and PLATELETS. It serves a variety of functions such as mediating leukocyte-platelet interactions, regulating trans-epithelial migration of POLYMORPHONUCLEAR LEUKOCYTES, and acting as a counter receptor for ALPHAM INTEGRIN. HN - 2013 MH - Junctional Adhesion Molecules UI - D062726 MN - D12.776.395.550.200.537 MN - D12.776.543.550.200.537 MN - D12.776.543.984.600 MN - D23.50.301.350.537 MS - A family of membrane glycoproteins localized to TIGHT JUNCTIONS that contain two extracellular Ig-like domains, a single transmembrane segment, and a cytoplasmic tail of variable length. HN - 2013 MH - Linear IgA Bullous Dermatosis UI - D062027 MN - C17.800.865.622 MN - C20.111.585 MS - Autoimmune disease characterized by subepidermal blisters and linear deposition of autoantibodies at the dermoepidermal junction. The accumulated autoantibodies are of IMMUNOGLOBULIN A and occasionally IMMUNOGLOBULIN G classes against epidermal BASEMENT MEMBRANE proteins. The dermatosis is sometimes associated with malignancies and use of certain drugs (e.g., VANCOMYCIN). HN - 2013 MH - Lipoblastoma UI - D062689 MN - C4.557.450.550.400.500 MS - Benign tumors of fatty tissues found in infancy and childhood. It is associated chromosomal aberrations that result in activation of an oncogene on chromosome band 8q12. AN - coordinate IM with precoordinated organ/neoplasm term (IM) HN - 2013 MH - Literature Based Discovery UI - D063369 MN - L1.178.682.99.325.750 MS - A process that searches for hidden and important connections among information embedded in published literature. HN - 2013 MH - Lunch UI - D062409 MN - F1.145.407.432.500.550 MN - F1.145.466.349.500.550 MN - J2.500.590.560 MS - The meal taken at midday. HN - 2013 BX - Lunchtime MH - Madin Darby Canine Kidney Cells UI - D061985 MN - A11.251.210.827 MN - A11.436.589 MS - An epithelial cell line derived from a kidney of a normal adult female dog. AN - almost always NIM with no subheadings; check ANIMALS & DOGS; do not routinely check FEMALE HN - 2013 MH - Mandibular Osteotomy UI - D063168 MN - E6.645.562.374 MS - Intraoral OSTEOTOMY of the lower jaw usually performed in order to correct MALOCCLUSION. HN - 2013 BX - Segmental Mandibulectomy FX - Mandibular Reconstruction MH - Mandibular Reconstruction UI - D063175 MN - E6.645.562.500 MS - The physical restoration of oromandibular defects. HN - 2013 FX - Mandibular Osteotomy MH - MARVEL Domain Containing 2 Protein UI - D062794 MN - D12.776.543.488.249 MN - D12.776.543.984.675 MS - A tight junction-associated MARVEL protein that may play a role in separating the endolymphatic and perilymphatic spaces of the ORGAN OF CORTI. Defects in the gene that codes for MARVELD2 protein are a cause of deafness autosomal recessive type 49. HN - 2013 MH - MARVEL Domain-Containing Proteins UI - D062792 MN - D12.776.543.488 MS - A family of proteins that share a domain with a four transmembrane-helix architecture referred to as the MARVEL domain. The MARVEL domain proteins play important role in vesicular trafficking and in the formation of TIGHT JUNCTIONS. HN - 2013 BX - MARVEL Domain Proteins FX - Tetraspanins MH - Maternal Death UI - D063130 MN - C13.703.401 MN - C23.550.260.730.500 MN - I1.880.735.607.500 MS - The death of the female parent. AN - do not confuse with MATERNAL MORTALITY, a statistical concept HN - 2013 MH - Maternal Serum Screening Tests UI - D062145 MN - E1.370.378.630.582 MS - Analysis of the level of specific BIOLOGICAL MARKERS in a pregnant woman's sera to identify those at risk for PREGNANCY COMPLICATIONS or BIRTH DEFECTS. HN - 2013 MH - Matrix Metalloproteinase Inhibitors UI - D061965 MN - D27.505.519.389.745.610 MS - Compounds that inhibit the enzyme activity or activation of MATRIX METALLOPROTEINASES. HN - 2013 MH - Maxillary Osteotomy UI - D063166 MN - E6.645.562.750 MS - Surgery of the upper jaw bone usually performed to correct upper and lower jaw misalignment. HN - 2013 MH - May-Thurner Syndrome UI - D062108 MN - C14.240.850.906 MN - C14.907.617.648 MN - C16.131.240.850.890 MS - A compression of ILIAC VEIN that results in a decreased flow in the vein and in the left LOWER EXTREMITY due to a vascular malformation. It may result in left leg EDEMA, pain, iliofemoral DEEP VENOUS THROMBOSIS and POSTTHROMBOTIC SYNDROME. Compression of the left common ILIAC VEIN by the right common ILIAC ARTERY against the underlying fifth LUMBAR VERTEBRA is the typical underlying malformation. HN - 2013 BX - Cockett Syndrome BX - Iliac Vein Compression Syndrome BX - Iliocaval Compression Syndrome FX - Constriction, Pathologic MH - MCF-7 Cells UI - D061986 MN - A11.251.210.190.630 MS - An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.) AN - almost always NIM with no subheadings; check HUMANS HN - 2013 MH - Meals UI - D062407 MN - F1.145.407.432.500 MN - F1.145.466.349.500 MN - J2.500.590 MS - A portion of the food eaten for the day, usually at regular occasions during the day. HN - 2013 BX - Dinner BX - Dinner Time BX - Mealtimes MH - Meaningful Use UI - D062527 MN - N4.761.744.500 MS - Using certified ELECTRONIC HEALTH RECORDS technology to improve quality, safety, efficiency, and reduce HEALTHCARE DISPARITIES; engage patients and families in their health care; improve care coordination; improve population and public health; while maintaining privacy and security. HN - 2013 MH - Medical Device Legislation UI - D062307 MN - N3.706.615.473.500 MS - Laws and regulations pertaining to devices used in medicine, proposed for enactment, or enacted by a legislative body. HN - 2013 MH - Medicalization UI - D062528 MN - I1.880.334 MS - A process by which nonmedical problems become defined and treated as medical problems, usually in terms of illnesses, or disorders. (Annu Rev Sociol 1992 18:209) HN - 2013 MH - meta-Aminobenzoates UI - D062368 MN - D2.241.223.100.50.300 MN - D2.455.426.559.389.127.20.452 MS - Aminobezoate derivatives that contain an amino group attached to carbon number 3 or 5 of the benzene ring structure. HN - 2013 MH - Metal-on-Metal Joint Prostheses UI - D061825 MN - E7.695.400.705 MS - Types of prosthetic joints in which both wear surfaces of the joint coupling are metallic. HN - 2013 MH - Methionyl Aminopeptidases UI - D063208 MN - D8.811.277.656.350.100.633 MS - Aminopeptidases that remove METHIONINE from the amino-terminus of a peptide chain, such as the initiator METHIONINE found on nascent peptide chains. HN - 2013 MH - Mitochondrial Degradation UI - D063306 MN - G4.299.630.500 MS - Proteolytic breakdown of the MITOCHONDRIA. HN - 2013 MH - Mitochondrial Dynamics UI - D063154 MN - G4.299.630.750 MS - The continuous remodeling of MITOCHONDRIA shape by fission and fusion in response to physiological conditions. HN - 2013 MH - Mitochondrial Turnover UI - D063269 MN - G4.299.630 MS - The cellular processes involved in adjustments to the MITOCHONDRIAL VOLUME, content, and activity, that depend on the energy demands of the cell. HN - 2013 MH - Molecular Docking Simulation UI - D062105 MN - E5.599.595.249 MN - L1.224.160.249 MS - A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. HN - 2013 BX - Molecular Docking Simulations FX - Protein Interaction Domains and Motifs FX - Protein Interaction Mapping FX - Protein Interaction Maps MH - Molecular Medicine UI - D062346 MN - H1.158.201.636.475 MN - H1.158.273.343.595.475 MN - H1.181.122.650.475 MN - H2.403.530 MS - The field of medicine concerned with understanding the biochemical basis of health and disease and involved in developing diagnostic and therapeutic methods that utilize MOLECULAR BIOLOGY techniques. AN - use for the discipline only (education, history, etc) HN - 2013 FX - Genetics, Medical MH - Motivational Interviewing UI - D062405 MN - F2.784.176.279.500 MN - F4.408.413.349.500 MN - N2.421.461.363.349.500 MS - It is a client-centered, directive method for eliciting intrinsic motivation to change using open-ended questions, reflective listening, and decisional balancing. This nonjudgmental, nonconfrontational interviewing style is designed to minimize a patient's resistance to change by creating an interaction that supports open discussion of risky or problem behavior. HN - 2013 MH - Myelin and Lymphocyte-Associated Proteolipid Proteins UI - D062806 MN - D10.570.780.249 MN - D12.776.543.488.374 MN - D12.776.543.620.264 MN - D12.776.543.990.681 MN - D12.776.641.580.249 MN - D12.776.816.249 MS - A family of MARVEL domain-containing proteolipid proteins involved in vesicular trafficking cycling between the GOLGI COMPLEX and the apical PLASMA MEMBRANE. HN - 2013 BX - Myelin and Lymphocyte-Associated Protein MH - Myelin-Oligodendrocyte Glycoprotein UI - D063308 MN - D12.776.395.550.583 MN - D12.776.543.550.572 MN - D12.776.543.620.550 MN - D12.776.641.580.530 MN - D23.50.422.625 MS - A transmembrane protein present in the MYELIN SHEATH of the CENTRAL NERVOUS SYSTEM. It is one of the main autoantigens implicated in the pathogenesis of MULTIPLE SCLEROSIS. AN - do not confuse with MYELIN-ASSOCIATED GLYCOPROTEIN or OLIGODENDROCYTE-MYELIN GLYCOPROTEIN HN - 2013 FX - Multiple Sclerosis MH - Myringosclerosis UI - D063371 MN - C9.218.636 MS - The formation of dense connective tissue in the TYMPANIC MEMBRANE that does not necessarily cause or lead to loss of hearing. HN - 2013 MH - N-Terminal Acetyltransferase A UI - D063209 MN - D8.811.913.50.134.423.100 MS - An N-terminal acetyltransferase subtype that consists of the Naa10p catalytic subunit and the Naa15p auxiliary subunit. The structure of this enzyme is conserved between lower and higher eukaryotes. It has specificity for N-terminal SERINE; ALANINE; THREONINE; GLYCINE; VALINE; and CYSTINE residues and acts on nascent peptide chains after the removal of the initiator METHIONINE by METHIONYL AMINOPEPTIDASES. HN - 2013 MH - N-Terminal Acetyltransferase B UI - D063210 MN - D8.811.913.50.134.423.200 MS - An N-terminal acetyltransferase subtype that consists of the Naa20p catalytic subunit and the Naa25p auxiliary subunit. The structure of this enzyme is conserved between YEASTS and HUMAN. It has specificity for the N-terminal METHIONINE of peptides where the next amino acid in the chain is either ASPARTATE; GLUTAMATE; ASPARAGINE; OR GLUTAMINE. HN - 2013 MH - N-Terminal Acetyltransferase C UI - D063211 MN - D8.811.913.50.134.423.300 MS - An N-terminal acetyltransferase subtype that consists of the Naa30p catalytic subunit, and the Naa35p and Naa38p auxiliary subunits. It has specificity for the N-terminal METHIONINE of peptides where the next amino acid in the chain is either LEUCINE; PHENYALANINE; ISOLEUCINE; or TRYPTOPHANE. HN - 2013 MH - N-Terminal Acetyltransferase D UI - D063212 MN - D8.811.913.50.134.407.74 MN - D8.811.913.50.134.423.400 MS - An N-terminal acetyltransferase subtype that consists of the Naa40p catalytic subunit. It has specificity for N-termini of HISTONE H2A and HISTONE H4. HN - 2013 MH - N-Terminal Acetyltransferase E UI - D063213 MN - D8.811.913.50.134.423.500 MS - An N-terminal acetyltransferase subtype that consists of the Naa50p catalytic subunit, and the Naa10p and Naa15p auxiliary subunits. It has specificity for the N-terminal METHIONINE of peptides where the next amino acid in the chain is hydrophobic. HN - 2013 MH - N-Terminal Acetyltransferase F UI - D063214 MN - D8.811.913.50.134.423.600 MS - An N-terminal acetyltransferase subtype that consists of the Naa60p catalytic subunit. It is found in higher eukayotes and displays a substrate specificity for the N-terminal METHIONINE of peptides where the next amino acid in the chain is either LEUCINE; LYSINE; PHENYALANINE; ISOLEUCINE; or TRYPTOPHANE. HN - 2013 MH - N-Terminal Acetyltransferases UI - D063206 MN - D8.811.913.50.134.423 MS - Enzymes that catalyze the transfer of an acetyl group, usually from ACETYL COENZYME A, to the N-terminus of a peptide chain. AN - do not confuse with AMINO-ACID N-ACETYLTRANSFERASE HN - 2013 MH - Narrative Therapy UI - D062525 MN - F4.754.570 MS - A form of PSYCHOTHERAPY that centers on the individuals as the experts in their own lives and views problems as separate from people. It is assumed that people have many skills, competencies, beliefs, values, commitments, and abilities that will assist them to reduce the influence of problems in their lives. HN - 2013 FX - Narration MH - Narrow Band Imaging UI - D062048 MN - E1.370.350.589.124 MN - E5.642.124 MS - Imaging techniques that use illumination created with several optical interference filters by which the frequency ranges are spectrally narrowed and light scatter is greatly reduced. Thus the reflected photons reconstituting the images are from distinct depths (the surface and deeper layers) of the object being imaged. HN - 2013 MH - Native Polyacrylamide Gel Electrophoresis UI - D063347 MN - E5.196.401.402.625 MN - E5.301.300.319.725 MS - Polyacrylamide gel electrophoresis under conditions in which the components, such as PROTEINS, being separated can remain in their naturally folded state. AN - for "blue native polyacrylamide gel electrophoresis" or BN-PAGE coordinate with the specific blue dye being used in the procedure HN - 2013 MH - NAV1.1 Voltage-Gated Sodium Channel UI - D062550 MN - D12.776.157.530.400.875.750.100 MN - D12.776.543.550.425.875.750.100 MN - D12.776.543.585.400.875.750.100 MN - D12.776.641.960.100 MS - A voltage-gated sodium channel subtype that is predominantly expressed in the CENTRAL NERVOUS SYSTEM. Defects in the SCN1A gene which codes for the alpha subunit of this sodium channel are associated with DRAVET SYNDROME, generalized epilepsy with febrile seizures plus, type 2 (GEFS+2), and familial hemiplegic migraine type 3. HN - 2013 BX - Voltage-Gated Sodium Channel Type 1 Subunit alpha FX - Epilepsies, Myoclonic MH - NAV1.2 Voltage-Gated Sodium Channel UI - D062551 MN - D12.776.157.530.400.875.750.200 MN - D12.776.543.550.425.875.750.200 MN - D12.776.543.585.400.875.750.200 MN - D12.776.641.960.200 MS - A voltage-gated sodium channel subtype that mediates the sodium ion permeability of excitable membranes. Defects in the SCN2A gene which codes for the alpha subunit of this sodium channel are associated with benign familial infantile seizures type 3, and early infantile epileptic encephalopathy type 11. HN - 2013 BX - Voltage-Gated Sodium Channel Type 2 Subunit alpha MH - NAV1.3 Voltage-Gated Sodium Channel UI - D062552 MN - D12.776.157.530.400.875.750.300 MN - D12.776.543.550.425.875.750.300 MN - D12.776.543.585.400.875.750.300 MN - D12.776.641.960.300 MS - A voltage-gated sodium channel subtype found in neuronal tissue that mediates the sodium ion PERMEABILITY of excitable membranes. HN - 2013 BX - Voltage-Gated Sodium Channel Type 3 Subunit alpha MH - NAV1.4 Voltage-Gated Sodium Channel UI - D062553 MN - D12.776.157.530.400.875.750.400 MN - D12.776.210.500.675 MN - D12.776.543.550.425.875.750.400 MN - D12.776.543.585.400.875.750.400 MS - A voltage-gated sodium channel subtype that mediates the sodium ion PERMEABILITY of SKELETAL MYOCYTES. Defects in the SCN4A gene, which codes for the alpha subunit of this sodium channel, are associated with several MYOTONIC DISORDERS. HN - 2013 BX - Voltage-Gated Sodium Channel Type 4 Subunit alpha FX - Hypokalemic Periodic Paralysis FX - Paralysis, Hyperkalemic Periodic MH - NAV1.5 Voltage-Gated Sodium Channel UI - D062554 MN - D12.776.157.530.400.875.750.500 MN - D12.776.543.550.425.875.750.500 MN - D12.776.543.585.400.875.750.500 MN - D12.776.641.960.500 MS - A voltage-gated sodium channel subtype that mediates the sodium ion PERMEABILITY of CARDIOMYOCYTES. Defects in the SCN5A gene, which codes for the alpha subunit of this sodium channel, are associated with a variety of CARDIAC DISEASES that result from loss of sodium channel function. HN - 2013 BX - Voltage-Gated Sodium Channel Type 5 Subunit alpha MH - NAV1.6 Voltage-Gated Sodium Channel UI - D062557 MN - D12.776.157.530.400.875.750.600 MN - D12.776.543.550.425.875.750.600 MN - D12.776.543.585.400.875.750.600 MN - D12.776.641.960.600 MS - A voltage-gated sodium channel subtype found widely expressed in neurons of the central and peripheral nervous systems. Defects in the SCN8A gene which codes for the alpha subunit of this sodium channel are associated with ATAXIA and cognitive deficits. HN - 2013 BX - Voltage-Gated Sodium Channel Type 8 Subunit alpha MH - NAV1.7 Voltage-Gated Sodium Channel UI - D062556 MN - D12.776.157.530.400.875.750.700 MN - D12.776.543.550.425.875.750.700 MN - D12.776.543.585.400.875.750.700 MN - D12.776.641.960.700 MS - A voltage-gated sodium channel subtype found widely expressed in nociceptive primary sensory neurons. Defects in the SCN9A gene, which codes for the alpha subunit of this sodium channel, are associated with several pain sensation-related disorders. HN - 2013 MH - NAV1.8 Voltage-Gated Sodium Channel UI - D062559 MN - D12.776.157.530.400.875.750.800 MN - D12.776.543.550.425.875.750.800 MN - D12.776.543.585.400.875.750.800 MN - D12.776.641.960.800 MS - A voltage-gated sodium channel subtype that is expressed in nociceptors, including spinal and trigeminal sensory neurons. It plays a role in the transmission of pain signals induced by cold, heat, and mechanical stimuli. HN - 2013 BX - Voltage-Gated Sodium Channel Type 10 Subunit alpha MH - NAV1.9 Voltage-Gated Sodium Channel UI - D062558 MN - D12.776.157.530.400.875.750.900 MN - D12.776.543.550.425.875.750.900 MN - D12.776.543.585.400.875.750.900 MN - D12.776.641.960.900 MS - A voltage-gated sodium channel subtype found in the neurons of the NERVOUS SYSTEM and DORSAL ROOT GANGLIA. It may play a role in the generation of heat and mechanical pain hypersensitivity. HN - 2013 BX - Voltage-Gated Sodium Channel Type 11 Subunit alpha MH - Neuromuscular Monitoring UI - D061886 MN - E1.370.520.567 MS - The use of peripheral nerve stimulation to assess transmission at the NEUROMUSCULAR JUNCTION, especially in the response to anesthetics, such as the intensity of NEUROMUSCULAR BLOCKADE by NEUROMUSCULAR BLOCKING AGENTS. HN - 2013 MH - Neurotology UI - D063165 MN - H2.403.600.500 MN - H2.403.810.526.500 MS - A subspecialty of otolaryngology dealing with the parts of the nervous system related to the ear. AN - use for the specialty only HN - 2013 MH - Non-Filarial Lymphedema UI - D062846 MN - C15.604.496.660 MS - A form of elephantiasis caused by soil particles which penetrate the skin of the foot. It is limited to tropical regions with soils of high volcanic content. HN - 2013 MH - Noninvasive Ventilation UI - D063087 MN - E2.41.625.591 MN - E2.880.820.657 MS - Techniques for administering artificial respiration without the need for INTRATRACHEAL INTUBATION. HN - 2013 MH - Nuclear Microscopy UI - D062345 MN - E1.370.350.515.744 MN - E5.595.744 MS - A method of simultaneously imaging and measuring elements at the submicron level. Nuclear microscopy uses a focused high-energy ion beam of PROTONS and ALPHA PARTICLES (a nuclear microprobe) to interact with the sample. The resulting emitted radiations are analyzed by a group of techniques simultaneously: PARTICLE INDUCED X RAY EMISSION SPECTROMETRY for minor and trace element identification; Rutherford Backscattering Spectroscopy to assess sample thickness and bulk elements such as carbon, hydrogen, oxygen, and nitrogen; and Scanning Transmission Ion Microscopy to assess sample structure and density. HN - 2013 FX - Electron Probe Microanalysis MH - Nursing Stations UI - D063187 MN - N2.278.388.620 MS - An area in a clinic, unit, or ward in a health care facility that serves as the administrative center for nursing care. (from Mosby's Medical Dictionary, 8th ed) HN - 2013 MH - Occludin UI - D062793 MN - D12.776.543.488.500 MN - D12.776.543.984.750 MS - A MARVEL domain protein that plays an important role in the formation and regulation of the TIGHT JUNCTION paracellular permeability barrier. HN - 2013 BX - Occludins MH - Odonata UI - D063191 MN - B1.50.500.131.617.634 MS - An order of insects comprising three suborders: Anisoptera, Zygoptera, and Anisozygoptera. They consist of dragonflies and damselflies. AN - for killing Odonata with insecticides, see note at INSECTICIDES HN - 2013 MH - Oligodendrocyte-Myelin Glycoprotein UI - D063345 MN - D12.776.395.550.448.775 MN - D12.776.543.484.500.775 MN - D12.776.543.550.418.775 MN - D12.776.543.620.895 MN - D12.776.641.580.895 MS - A glycosylated extracellular myelin protein found on the MYELIN SHEATH of the CENTRAL NERVOUS SYSTEM. It is linked to the cell surface via a GLYCOSYLPHOSPHATIDYLINOSITOL LINKAGE. AN - do not confuse with MYELIN-OLIGODENDROCYTE GLYCOPROTEIN HN - 2013 MH - One-Lung Ventilation UI - D061810 MN - E2.41.625.657 MS - Techniques for supplying artificial respiration to a single lung. AN - /instrum: consider also VENTILATORS, MECHANICAL HN - 2013 MH - Operative Time UI - D061646 MN - E4.614.374.500 MN - N2.421.585.753.374.500 MS - The duration of a surgical procedure in hours and minutes. HN - 2013 MH - Optical Imaging UI - D061848 MN - E1.370.350.589 MN - E5.642 MS - The use of light interaction (scattering, absorption, and fluorescence) with biological tissue to obtain morphologically based information. It includes measuring inherent tissue optical properties such as scattering, absorption, and autofluorescence; or optical properties of exogenous targeted fluorescent molecular probes such as those used in optical MOLECULAR IMAGING, or nontargeted optical CONTRAST AGENTS. HN - 2013 MH - Optically Stimulated Luminescence Dosimetry UI - D062791 MN - E5.799.638.602 MN - N6.850.810.370.365 MS - The use of a radiation monitoring device composed of material which emits light after being illuminated. The amount of light emitted is proportional to the amount of IONIZING RADIATION to which the material has been previously exposed. HN - 2013 BX - Optically Stimulated Luminescent Dosimetry MH - Optogenetics UI - D062308 MN - E5.393.667 MS - The combination of genetic and optical methods in controlling specific events with temporal precision in targeted cells of a functioning intact biological system. HN - 2013 MH - Organ Dysfunction Scores UI - D063305 MN - E5.318.308.250.475.410 MN - N5.715.360.300.375.375.181 MN - N6.850.520.308.250.475.181 MS - Ratings that express, in numerical values, the degree of impairment or abnormality in the function of specific organs. HN - 2013 FX - Multiple Organ Failure MH - Organically Modified Ceramics UI - D063225 MN - D2.715.312 MN - D5.750.593 MN - D25.264.688 MN - D25.339.291.551 MN - D25.720.593 MN - J1.637.51.339.291.476 MN - J1.637.51.720.628 MS - Organic-inorganic hybrid polymers developed primarily for DENTAL RESTORATION. They typically contain a defined mixture of ORGANOSILICON COMPOUNDS; CERAMICS; and organic POLYMERS. HN - 2013 MH - Organofluorophosphonates UI - D063066 MN - D2.705.429.750 MS - A subclass of organophosphates that have a FLUORINE atom substituted for one of the OXYGEN atoms. HN - 2013 MH - Organophosphate Poisoning UI - D062025 MN - C25.723.717 MS - Poisoning due to exposure to ORGANOPHOSPHORUS COMPOUNDS, such as ORGANOPHOSPHATES; ORGANOTHIOPHOSPHATES; and ORGANOTHIOPHOSPHONATES. AN - coordinate with specific organophosphate if pertinent HN - 2013 MH - Organophosphonates UI - D063065 MN - D2.705.429 MS - Carbon-containing phosphonic acid compounds. Included under this heading are compounds that have carbon bound to either OXYGEN atom or the PHOSPHOROUS atom of the (P=O)O2 structure. HN - 2013 MH - Organothiophosphates UI - D063086 MN - D2.705.400.625 MN - D2.705.539.345 MN - D2.886.300.692 MS - Carbon-containing thiophosphoric acid derivatives. Included under this heading are compounds that have carbon bound to either SULFUR atom, or the OXYGEN atom of the SPO3 core structure. HN - 2013 MH - Organothiophosphonates UI - D063085 MN - D2.705.429.812 MN - D2.705.539.692 MN - D2.886.300.846 MS - Carbon-containing thiophosphonic acid compounds. Included under this heading are compounds that have carbon bound to either SULFUR atom, PHOSPHOROUS atom, or the OXYGEN atom of the SPO2 core structure. HN - 2013 MH - ortho-Aminobenzoates UI - D062367 MN - D2.241.223.100.50.400 MN - D2.455.426.559.389.127.20.906 MS - Benzoic acids, salts, or esters that contain an amino group attached to carbon number 2 or 6 of the benzene ring structure. HN - 2013 MH - Oxaloacetic Acid UI - D062907 MN - D2.241.81.337.593.812.750 MN - D2.241.755.648.750 MS - A dicarboxylic acid ketone that is an important metabolic intermediate of the CITRIC ACID CYCLE. It can be converted to ASPARTIC ACID by ASPARTATE TRANSAMINASE. HN - 2013 MH - Ozone Depletion UI - D062966 MN - G16.500.240.547 MN - N6.230.300.100.700.500 MS - A shift in the balance between production and destruction of STRATOSPHERIC OZONE that results in a decline of the amount of OZONE in the lower stratosphere. HN - 2013 MH - para-Aminobenzoates UI - D062366 MN - D2.241.223.100.50.500 MN - D2.455.426.559.389.127.20.937 MS - Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure. HN - 2013 MH - Parental Death UI - D063129 MN - C23.550.260.730 MN - I1.880.735.607 MS - The death of the father or mother or another person in this role. HN - 2013 MH - Patient Acuity UI - D062072 MN - E5.318.308.250.475.456 MN - N5.715.360.300.375.375.364 MN - N6.850.520.308.250.475.364 MS - An assessment of a patient's illness, its chronicity, severity, and other qualitative aspects. HN - 2013 MH - Patient Handoff UI - D062209 MN - N4.590.233.727.210.249 MN - N5.715.840.500 MS - The transferring of patient care responsibility from one health-care professional to another. HN - 2013 MH - Patient Medication Knowledge UI - D063046 MN - N2.421.143.827.407.228.500.500 MN - N2.421.726.407.228.500.500 MS - Patient health knowledge related to medications including what is being used and why as well as instructions and precautions. HN - 2013 MH - Patient Navigation UI - D062526 MN - N4.590.720.500 MS - The process of helping patients to effectively and efficiently use the health care system when faced with one or more of these challenges: (1) choosing, understanding, and using health coverage or applying for assistance when uninsured; (2) choosing, using, and understanding different types of health providers and services; (3) making treatment decisions; and (4) managing care received by multiple providers. HN - 2013 MH - Percutaneous Coronary Intervention UI - D062645 MN - E4.100.814.529.968 MN - E4.800.382.968 MS - A family of percutaneous techniques that are used to manage CORONARY OCCLUSION, including standard balloon angioplasty (PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY), the placement of intracoronary STENTS, and atheroablative technologies (e.g., ATHERECTOMY; ENDARTERECTOMY; THROMBECTOMY; PERCUTANEOUS TRANSLUMINAL LASER ANGIOPLASTY). PTCA was the dominant form of PCI, before the widespread use of stenting. HN - 2013 MH - Perforator Flap UI - D061525 MN - A10.850.710.750 MN - E7.862.710.750 MS - A mass of tissue for transplantation that includes the skin and/or the SUBCUTANEOUS FAT, and the perforating blood vessel that traverses the underlying tissue to supply blood to the skin. Perforator flaps are named after the anatomical region or muscle from where they are transplanted and/or the perforating blood vessel. HN - 2013 MH - Personal Narratives UI - D062210 MN - V2.170.875 MS - Works consisting of accounts of individual experience in relation to a particular field or of participation in related activities. AN - CATALOG: Use for single as well as for collections of self-described accounts on specific topics and for personal reminiscences on specific topics. Use AUTOBIOGRAPHY for self-described narratives of a person's life. HN - 2013 MH - Personal Narratives as Topic UI - D063545 MN - K1.517.211.753 MS - Works about accounts of individual experience in relation to a particular field or of participation in related activities. HN - 2013 MH - Phosphoramides UI - D063088 MN - D1.695.625.675.650.425 MN - D2.705.672 MS - Amide derivatives of phosphoric acid such as compounds that include the phosphoric triamide (P(=O)(N)(N)(N)) structure. HN - 2013 MH - Physical Therapist Assistants UI - D063372 MN - M1.526.485.67.738 MN - N2.360.67.732 MS - Persons who, under the supervision of licensed PHYSICAL THERAPISTS, provide patient treatment using various PHYSICAL THERAPY THECHNIQUES. HN - 2013 FX - Physical Therapy Modalities FX - Physical Therapy Specialty MH - Plant Development UI - D063245 MN - G7.700.320.625 MN - G15.744.723 MS - Processes orchestrated or driven by a plethora of genes, plant hormones, and inherent biological timing mechanisms facilitated by secondary molecules, which result in the systematic transformation of plants and plant parts, from one stage of maturity to another. AN - general or unspecified; prefer /growth with specific plant HN - 2013 MH - Plant Dispersal UI - D063148 MN - G15.744.735 MS - The physical distribution of plants in various forms and stages of development through time and space. HN - 2013 MH - Plant Mucilage UI - D062087 MN - D5.750.78.764 MN - D9.698.709 MN - D25.720.99.718 MS - A type of viscous polysaccharide that is secreted from PLANTS. It has natural properties that are useful in the formulation of ADHESIVES. AN - do not confuse with MUCILAGES, ADHESIVE see ADHESIVES HN - 2013 FX - Adhesives MH - Pneumorrhachis UI - D063205 MN - C10.228.854.583 MS - Presence of air or gas within the spinal canal cavity (EPIDURAL SPACE; or SUBARACHNOID SPACE). It may result from traumatic injuries, emphysema, infection and other conditions. It can also develop as a complication of various SURGICAL PROCEDURES (e.g., MYELOGRAPHY). HN - 2013 MH - Polycomb Repressive Complex 1 UI - D063150 MN - D5.500.781.100 MN - D8.811.464.938.750.280 MN - D12.776.660.235.600.100 MN - D12.776.664.235.800.100 MN - D12.776.930.700.890.100 MS - A multisubunit polycomb protein complex with affinity for CHROMATIN that contains methylated HISTONE H3. It contains an E3 ubiquitin ligase activity that is specific for HISTONE H2A and works in conjunction with POLYCOMB REPRESSIVE COMPLEX 2 to effect EPIGENETIC REPRESSION. HN - 2013 MH - Polycomb Repressive Complex 2 UI - D063151 MN - D5.500.781.750 MN - D8.811.913.555.500.800.400.500 MN - D12.776.660.235.600.200 MN - D12.776.664.235.800.200 MN - D12.776.930.700.890.200 MS - A multisubunit polycomb protein complex that catalyzes the METHYLATION of chromosomal HISTONE H3. It works in conjunction with POLYCOMB REPRESSIVE COMPLEX 1 to effect EPIGENETIC REPRESSION. HN - 2013 MH - Polycomb-Group Proteins UI - D063146 MN - D5.500.781 MN - D12.776.660.235.600 MN - D12.776.664.235.800 MN - D12.776.930.700.890 MS - A family of proteins that play a role in CHROMATIN REMODELING. They are best known for silencing HOX GENES and the regulation of EPIGENETIC PROCESSES. HN - 2013 MH - Pregnancy, Heterotopic UI - D063192 MN - C13.703.769 MS - MULTIPLE PREGNANCY at two different implantation sites, involving intrauterine and extrauterine (ECTOPIC PREGNANCY). HN - 2013 MH - Premature Ejaculation UI - D061686 MN - C12.294.644.743 MN - F3.800.800.700 MS - The emission of SEMEN and seminal fluid during the act of preparation for sexual intercourse, i.e. before there is penetration, or shortly after penetration. HN - 2013 FX - Ejaculation MH - Prescription Drug Misuse UI - D063487 MN - E2.319.754 MS - Improper use of drugs or medications outside the intended purpose, scope, or guidelines for use. This is in contrast to MEDICATION ADHERENCE, and distinguished from DRUG ABUSE, which is a deliberate or willful action frequently associated with psychological disorders. HN - 2013 FX - Drug Toxicity FX - Inappropriate Prescribing FX - Medication Errors FX - Substance-Related Disorders MH - Prodromal Symptoms UI - D062706 MN - C23.888.672 MN - E1.599 MS - Clinical or physiological indicators that precede the onset of disease. HN - 2013 MH - Proteasome Inhibitors UI - D061988 MN - D27.505.519.389.745.705 MS - Compounds that inhibit the function or proteolytic action of the PROTEASOME. HN - 2013 MH - Protein Degradation End Products UI - D062106 MN - D12.776.643 MS - Degraded protein components that are found within TISSUES, bodily fluids, and cells under certain pathological conditions. They are largely formed through chemical reactions which occur during non-physiological conditions such as ISCHEMIA; HYPERGLYCEMIA; and PHYSIOLOGICAL STRESS. HN - 2013 MH - Proton Therapy UI - D061766 MN - E2.815.435 MS - The use of an external beam of PROTONS as radiotherapy. AN - coordinate with disease /radiother HN - 2013 MH - Public Health Surveillance UI - D062486 MN - E5.318.308.250.700.324 MN - N5.715.360.300.375.625.324 MN - N6.850.520.308.250.700.324 MN - N6.850.780.675.487 MS - The ongoing, systematic collection, analysis, and interpretation of health-related data with the purpose of preventing or controlling disease or injury, or of identifying unusual events of public health importance, followed by the dissemination and use of information for public health action. (From Am J Prev Med 2011;41(6):636) HN - 2013, use Population Surveillance 1990-2012 MH - Pulse Wave Analysis UI - D063177 MN - E1.370.370.680 MS - Evaluation of the contour of the PULSE waves which vary in different parts of the circulation and depend on physiological as well as pathophysiological conditions of the individual. AN - note entry term PULSE WAVE VELOCITY: do not confuse with BLOOD FLOW VELOCITY HN - 2013 MH - Quillaja Saponins UI - D062605 MN - D9.408.782.512 MS - Natural detergents made up of a heterogeneous mixture of molecules having a triterpenoid core structure. They vary in aglycone (sapogenin) and sugar moieties, including glucose. HN - 2013; use Quillaja 2003-2012 MH - Racism UI - D063505 MN - F1.145.813.550.500 MN - F1.145.813.629.625 MN - F1.829.595.500 MN - I1.880.735.768.500 MS - Differential treatment or unequal access to opportunities, based on group membership such as origin or ethnicity. HN - 2013; use PREJUDICE 1994-2012 MH - Rana clamitans UI - D063188 MN - B1.50.150.900.90.180.708.210 MS - A species of the family Ranidae which occurs primarily in the eastern half of the United States and Canada. Two subspecies exist, commonly referred to as green frog (R. c. melanota) and bronze frog (R. c. clamitans). HN - 2013 BX - Frog, Green BX - Green Frog MH - Re-Epithelialization UI - D062326 MN - G4.299.730 MN - G13.750.829.755 MN - G16.100.856.891.750 MS - Reconstitution of eroded or injured EPITHELIUM by proliferation and migration of EPITHELIAL CELLS from below or adjacent to the damaged site. HN - 2013 MH - Receptors, Artificial UI - D062165 MN - D12.776.260.698.387 MN - D12.776.543.750.66 MN - D12.776.826.387 MN - D12.776.930.669.387 MN - J1.637.87.750 MS - Receptors that are created by SYNTHETIC CHEMISTRY TECHNIQUES. They are usually designed to mimic endogenous CELL SURFACE RECEPTORS. HN - 2013 MH - Respiratory Aspiration of Gastric Contents UI - D063466 MN - C6.405.117.119.500.484.500.500 MN - C8.618.749.500 MN - C23.550.773.500 MS - Inhaling refluxed gastric or duodenal contents. HN - 2013; use RESPIRATORY ASPIRATION 2007-2012 FX - Pneumonia, Aspiration MH - Retrognathia UI - D063173 MN - C5.660.207.540.460.827 MN - C7.320.610.827 MN - C7.650.500.460.827 MN - C16.131.850.500.460.827 MS - A physical misalignment of the upper (maxilla) and lower (mandibular) jaw bones in which either or both recede relative to the frontal plane of the forehead. HN - 2013; use Retrognathism 2000-2012 FX - Malocclusion FX - Mandibular Advancement MH - Return to Work UI - D062707 MN - I3.946.449 MN - N1.824.245.725 MS - Resumption of normal work routine following a hiatus or period of absence due to injury, disability, or other reasons. HN - 2013 BX - Return-to-Work FX - Rehabilitation MH - rho Guanine Nucleotide Dissociation Inhibitor alpha UI - D062948 MN - D12.644.360.325.225.500.100 MN - D12.776.402.225.500.100 MN - D12.776.476.325.225.500.100 MS - An abundantly-expressed rho GDP-dissociation inhibitor subtype that regulates a broad variety of RHO GTPASES. HN - 2013 MH - rho Guanine Nucleotide Dissociation Inhibitor beta UI - D062949 MN - D12.644.360.325.225.500.200 MN - D12.776.402.225.500.200 MN - D12.776.476.325.225.500.200 MS - A rho GDP-dissociation inhibitor subtype that is highly expressed in hematopoietic cells and in LYMPHOCYTES. The expression of this subtype is associated with the regulation of CELL PROLIFERATION; TUMORIGENESIS; and APOPTOSIS. HN - 2013 MH - rho Guanine Nucleotide Dissociation Inhibitor gamma UI - D062950 MN - D12.644.360.325.225.500.300 MN - D12.776.402.225.500.300 MN - D12.776.476.325.225.500.300 MS - A rho GDP-dissociation inhibitor subtype that has a unique C-terminal alpha helical membrane-binding domain. It is found bound to CYTOPLASMIC VESICLES such as those associated with the GOLGI APPARATUS. HN - 2013 MH - rho-Specific Guanine Nucleotide Dissociation Inhibitors UI - D062947 MN - D12.644.360.325.225.500 MN - D12.776.402.225.500 MN - D12.776.476.325.225.500 MS - A subcategory of guanine nucleotide dissociation inhibitors that are specific for RHO GTP-BINDING PROTEINS. HN - 2013 MH - RNA, Long Untranslated UI - D062085 MN - D13.444.735.790.375 MS - A class of untranslated RNA molecules that are typically greater than 200 nucleotides in length and do not code for proteins. Members of this class have been found to play roles in transcriptional regulation, post-transcriptional processing, CHROMATIN REMODELING, and in the epigenetic control of chromatin. HN - 2013 MH - RxNorm UI - D062245 MN - L1.143.506.598.400.778 MN - L1.700.508.280.875 MS - A standardized nomenclature for clinical drugs and drug delivery devices. It links its names to many of the drug vocabularies commonly used in pharmacy management. AN - CATALOG: Use NAF HN - 2013 MH - Secondary Care UI - D063127 MN - N4.452.758.849.775 MN - N5.300.745 MS - Specialized healthcare delivered as a follow-up or referral from a PRIMARY CARE provider. HN - 2013 MH - Sexism UI - D063507 MN - F1.145.813.550.750 MN - F1.145.813.629.750 MN - F1.829.595.750 MS - Prejudice or discrimination based on gender or behavior or attitudes that foster stereotyped social roles based on gender. HN - 2013; use PREJUDICE 1994-2012 BX - Gender Bias BX - Sex Bias MH - Sf9 Cells UI - D061987 MN - A11.251.210.891 MS - Cell line derived from SF21 CELLS which are a cell line isolated from primary explants of SPODOPTERA FRUGIPERDA pupal tissue. AN - almost always NIM with no subheadings; check ANIMALS and add SPODOPTERA (NIM) HN - 2013 MH - Sialic Acid Binding Ig-like Lectin 1 UI - D063267 MN - D12.776.503.921.100 MN - D23.50.301.264.35.913.100 MN - D23.101.100.110.929.100 MS - A sialic acid binding lectin that was originally identified as an adhesion molecule for inflammatory MACROPHAGES and activated MONOCYTES. This protein is the largest known siglec subtype and contains 16 immunoglobulin C2-set domains. It plays a role in cell to cell interactions and interactions with BACTERIA. HN - 2013 MH - Sialic Acid Binding Ig-like Lectin 3 UI - D063268 MN - D12.776.503.921.400 MN - D23.50.301.264.35.913.300 MN - D23.50.301.264.900.565 MN - D23.101.100.110.929.300 MN - D23.101.100.900.565 MS - A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE. HN - 2013 MH - Sialic Acid Binding Immunoglobulin-like Lectins UI - D063265 MN - D12.776.503.921 MN - D23.50.301.264.35.913 MN - D23.101.100.110.929 MS - A family of SIALIC ACID binding proteins found in vertebrate species. They are transmembrane proteins which act as cell surface receptors for a variety of sialylated GLYCOCONJUGATES. While a subset of siglec protein subtypes are evolutionarily conserved between mammalian species, there are many others that are species specific. HN - 2013 MH - Silorane Resins UI - D062047 MN - D2.715.650.850 MN - D5.750.716.822.461.500 MN - D5.750.900.925 MN - D25.339.291.300.500 MN - J1.637.51.339.291.300.500 MS - Polymeric resins containing a combination of SILOXANES and OXIRANES. HN - 2013 MH - Singing UI - D063346 MN - F1.145.113.55.800.500 MN - G9.772.770.680.500 MS - The act of manipulating voice to produce sounds augmented by musical tonality and rhythm. HN - 2013 MH - Single-Domain Antibodies UI - D061905 MN - D12.644.541.500.650.500.900 MN - D12.776.124.486.485.680.650.500.900 MN - D12.776.124.790.651.680.650.500.900 MN - D12.776.377.715.548.680.650.500.897 MS - An immunoglobulin fragment composed of one variable domain from an IMMUNOGLOBULIN HEAVY CHAIN or IMMUNOGLOBULIN LIGHT CHAIN. HN - 2013 FX - Single-Chain Antibodies MH - Skin Cream UI - D063465 MN - E2.547.800.500 MN - J1.516.213.249 MS - A water-soluble medicinal preparation applied to the skin. HN - 2013 MH - Skin Lightening Preparations UI - D062327 MN - D27.720.269.750 MN - J1.516.213.500 MS - Substances used to obtain a lighter skin complexion or to treat HYPERPIGMENTATION disorders. HN - 2013 MH - Smoke-Free Policy UI - D061845 MN - I1.655.249 MS - Prohibition against tobacco smoking in specific areas to control TOBACCO SMOKE POLLUTION. HN - 2013 MH - Snacks UI - D062410 MN - F1.145.407.432.500.775 MN - F1.145.466.349.500.775 MN - J2.500.590.780 MS - Foods eaten between MEALTIMES. HN - 2013 BX - Snacking BX - Snacktime MH - Social Discrimination UI - D063508 MN - F1.145.813.629 MS - Group behavior toward others by virtue of their group membership. AN - do not confuse with DISCRIMINATION (PSYCHOLOGY) HN - 2013; use PREJUDICE 1982-2012 MH - Social Marginalization UI - D062487 MN - F1.145.813.817 MN - I1.880.696 MS - Individuals or groups, excluded from participation in the economic, social, and political activities of membership in a community. HN - 2013 MH - Sodium Channel Agonists UI - D062687 MN - D27.505.519.562.625 MS - A class of drugs that stimulate sodium influx through cell membrane channels. HN - 2013 MH - Solid Waste UI - D062611 MN - D20.944.730 MN - N6.850.460.710.730 MS - Garbage, refuse, or sludge, or other discarded materials from a wastewater treatment plant, water supply treatment plant, and air pollution control facility that include solid, semi-solid, or contained material. It does not include materials dissolved in domestic sewage, irrigation return flows, or industrial discharges. HN - 2013 FX - Refuse Disposal MH - Spatial Analysis UI - D062206 MN - E5.318.740.933 MN - N5.715.360.750.746 MN - N6.850.520.830.933 MS - Techniques which study entities using their topological, geometric, or geographic properties. HN - 2013 FX - Geographic Information Systems MH - Spatio-Temporal Analysis UI - D062211 MN - E5.318.740.933.500 MN - N5.715.360.750.746.500 MN - N6.850.520.830.933.500 MS - Techniques which study entities using their topological, geometric, or geographic properties and include the dimension of time in the analysis. HN - 2013 FX - Space-Time Clustering MH - Spinal Cord Stimulation UI - D062187 MN - E2.342.735 MN - E2.779.468.699 MS - Application of electric current to the spine for treatment of a variety of conditions involving innervation from the spinal cord. HN - 2013 MH - Steatocystoma Multiplex UI - D062685 MN - C16.131.831.350.856.500 MN - C16.320.850.250.856.500 MN - C17.800.529.594.500 MN - C17.800.804.350.856.500 MN - C17.800.827.250.856.500 MS - A disorder characterized by multiple, wide spread cutaneous cysts that often become inflamed and rupture. It is caused by the same mutations in the gene coding for KRT-17 that are causative mutations for Pachyonychia congenita, Type 2. Natal teeth involvement is sometimes associated with steatocystoma multiplex. HN - 2013 FX - Keratin-17 MH - Strategic Stockpile UI - D062205 MN - N5.300.420.700 MN - N6.230.100.35.500 MS - Planned and coordinated pre-event accumulation of ESSENTIAL DRUGS and medical supplies. HN - 2013 MH - Stratospheric Ozone UI - D062952 MN - D1.362.670.600.500 MN - G16.500.275.63.700 MN - N6.230.300.100.700 MS - Ozone in the Earth's stratosphere. It is produced continuously by the action of solar ULTRAVIOLET RAYS on oxygen in the stratosphere. The stratospheric ozone (especially at the ozone layer) blocks much of the solar UV radiation of wavelengths of 320 nanometers or less from being transmitted to lower ATMOSPHERE of the Earth. HN - 2013 BX - Ozone Layer MH - Symptom Assessment UI - D063189 MN - E1.370.872 MS - Evaluation of manifestations of disease. HN - 2013 MH - Synaptogyrins UI - D062805 MN - D12.776.543.488.750 MN - D12.776.543.990.831 MN - D12.776.641.775 MS - A subfamily of MARVEL domain-containing proteins that are found in SYNAPTIC VESICLES, where they may play a role in modulating neuronal signaling. HN - 2013 MH - Tertiary Care Centers UI - D062606 MN - N2.278.421.830 MS - A medical facility which provides subspecialty expertise for patients often referred from centers where they received SECONDARY CARE. AN - TERTIARY CARE is also available HN - 2013 FX - Academic Medical Centers FX - Hospitals, Special FX - Referral and Consultation MH - Tertiary Healthcare UI - D063128 MN - N4.452.758.849.887 MN - N5.300.787 MS - Care of a highly technical and specialized nature, provided in a medical center, usually one affiliated with a university, for patients with unusually severe, complex, or uncommon health problems. AN - TERTIARY CARE CENTERS is also available HN - 2013 BX - Tertiary Care MH - Thermometry UI - D062125 MN - E5.933 MS - Measurement of the temperature of a material, or of the body or an organ by various temperature sensing devices which measure changes in properties of the material that vary with temperature, such as ELASTICITY; MAGNETIC FIELDS; or LUMINESCENCE. AN - coordinate with specific measuring method or property measured HN - 2013 MH - Tiapride Hydrochloride UI - D063325 MN - D2.92.471.869 MN - D2.241.223.100.100.933 MN - D2.455.426.559.389.127.85.933 MS - Benzamide derivative with dopamine antagonist actions similar to SULPIRIDE. HN - 2013; use BENZAMIDES 1980-2012 BX - Tiapride BX - Tiapride Monohydrochloride MH - Tight Junction Proteins UI - D062725 MN - D12.776.543.984 MS - Proteins that take part in the formation or structure of TIGHT JUNCTIONS. HN - 2013 MH - Time-to-Pregnancy UI - D061685 MN - G8.686.210.500 MS - Time interval, or number of non-contraceptive menstrual cycles that it takes for a couple to conceive. HN - 2013 FX - Reproductive History MH - Time-to-Treatment UI - D061665 MN - E2.760.928 MN - N2.421.585.928 MS - The interval of time between onset of symptoms and receiving therapy. HN - 2013 BX - Time to Treatment MH - Tobacco Products UI - D062789 MN - J1.637.836 MS - Substances and products derived from NICOTIANA TABACUM. HN - 2013 BX - Cigarettes BX - Cigars MH - Transcription Elongation, Genetic UI - D061805 MN - G2.111.87.847.562 MN - G2.149.115.847.562 MN - G5.355.310.700.562 MS - The lengthening of a nascent RNA molecule by RNA POLYMERASE during transcription. HN - 2013 MH - Transcription Initiation, Genetic UI - D061785 MN - G2.111.87.847.625 MN - G2.149.115.847.625 MN - G5.355.310.700.625 MS - The process that starts the transcription of an RNA molecule. It includes the assembly of the initiation complex and establishment of the start site. HN - 2013 MH - Transcription Termination, Genetic UI - D061806 MN - G2.111.87.847.687 MN - G2.149.115.847.687 MN - G5.355.310.700.687 MS - The discontinuation of transcription at the end of a transcription unit, including the recognition of termination sites and release of the newly synthesized RNA molecule. HN - 2013 MH - Transgendered Persons UI - D063106 MN - M1.909 MS - Persons having a sense of persistent identification with, and expression of, gender-coded behaviors not typically associated with one's anatomical sex at birth, and with or without a desire to undergo SEX REASSIGNMENT PROCEDURES. HN - 2013 FX - Disorders of Sex Development FX - Gender Identity FX - Health Services for Transgendered Persons FX - Transsexualism MH - Transtympanic Micropressure Treatment UI - D062086 MN - E4.580.450.802 MS - The intermittent delivery of pulses of air pressure (5 -20 cmH2O) to the middle ear space through a TYMPANOSTOMY tube. HN - 2013 FX - Endolymphatic Hydrops FX - Meniere Disease MH - Tropical Diseases UI - D062310 MN - C23.996 MS - Diseases which are normally prevalent in or frequently associated with tropical regions of the world. HN - 2013 MH - Urinary Catheters UI - D062885 MN - E7.132.625 MS - Catheters inserted into the URINARY BLADDER or kidney for therapeutic or diagnostic purposes. HN - 2013 FX - Urinary Catheterization MH - Uterine Myomectomy UI - D063186 MN - E4.950.300.941 MS - Surgical removal of a LEIOMYOMA of the UTERUS. HN - 2013 MH - Vaccines, Adenovirus UI - D062705 MN - D20.215.894.899.24 MS - Vaccines used to prevent infection by any virus from the family ADENOVIRIDAE. AN - use only for vaccines to prevent infection by ADENOVIRIDAE; not for adenovirus vector-based synthetic vaccines to prevent other infections (for example: adenovirus 5, rabies glycoprotein recombinant vaccine) HN - 2013 BX - Adenovirus Vaccines MH - Vaccines, Live, Unattenuated UI - D062690 MN - D20.215.894.882 MS - Live vaccines prepared from microorganisms without their virulence altered. Examples include smallpox (vaccinia) and adenovirus vaccines. AN - coordinate NIM with specific vaccine (IM) HN - 2013 BX - Vaccines, Unattenuated MH - Value-Based Purchasing UI - D062505 MN - N3.219.521.576.343.981 MS - Purchasers are provided information on the quality of health care, including patient outcomes and health status, with data on the dollar outlays going towards health. The focus is on managing the use of the health care system to reduce inappropriate care and to identify and reward the best-performing providers. (from http://www.ahrq.gov/qual/meyerrpt.htm accessed 11/25/2011) HN - 2013 MH - Vascular Access Devices UI - D062666 MN - E7.132.750 MS - Devices to be inserted into veins or arteries for the purpose of carrying fluids into or from a peripheral or central vascular location. They may include component parts such as catheters, ports, reservoirs, and valves. They may be left in place temporarily for therapeutic or diagnostic purposes. HN - 2013; for VASCULAR ACCESS PORTS use CATHETERS, INDWELLING 1990-2012; for INTRA-ARTERIAL LINES use CATHETERS, INDWELLING 1987-2012; for VENOUS RESERVOIRS use CATHETERS, INDWELLING 1998-2012 BX - Arterial Lines BX - Intra-Arterial Lines BX - Vascular Access Ports BX - Venous Reservoirs MH - Virtual Reality Exposure Therapy UI - D063367 MN - F4.754.137.506.662 MS - Treatment technique in a virtual environment which allows the participant to experience a sense of presence in an immersive, computer-generated, three-dimensional, interactive environment that minimizes avoidance behavior and facilitates emotional involvement. (from Curr Psychiatry Rep (2010) 12:298) HN - 2013 MH - Voltage-Gated Sodium Channel Agonists UI - D061585 MN - D27.505.519.562.625.500 MS - Compounds that either stimulate the opening or prevent closure of VOLTAGE-GATED SODIUM CHANNELS. HN - 2013 BX - Voltage-Gated Sodium Channel Activators MH - Voltage-Gated Sodium Channel beta Subunits UI - D062546 MN - D12.776.157.530.400.875.750.960 MN - D12.776.543.550.425.875.750.970 MN - D12.776.543.585.400.875.750.970 MN - D12.776.641.960.970 MS - Voltage-gated sodium channel subunits that play a role in the assembly, expression, and functional modulation of the sodium channel. They form a heterotrimeric complex with the pore-forming sodium channel alpha subunits. HN - 2013 MH - Voltage-Gated Sodium Channel beta-1 Subunit UI - D062547 MN - D12.776.157.530.400.875.750.960.100 MN - D12.776.543.550.425.875.750.970.100 MN - D12.776.543.585.400.875.750.970.100 MN - D12.776.641.960.970.100 MS - A voltage-gated sodium channel beta subunit abundantly expressed in SKELETAL MUSCLE; HEART; and BRAIN. It non-covalently associates with voltage-gated alpha subunits. Defects in the SCN1B gene, which codes for this beta subunit, are associated with generalized epilepsy with febrile seizures plus, type 1, and Brugada syndrome 5. HN - 2013 FX - Brugada Syndrome MH - Voltage-Gated Sodium Channel beta-2 Subunit UI - D062548 MN - D12.776.157.530.400.875.750.960.200 MN - D12.776.543.550.425.875.750.970.200 MN - D12.776.543.585.400.875.750.970.200 MN - D12.776.641.960.970.200 MS - A voltage-gated sodium channel beta subunit that binds covalently to voltage-gated alpha subunits. HN - 2013 MH - Voltage-Gated Sodium Channel beta-3 Subunit UI - D062549 MN - D12.776.157.530.400.875.750.960.300 MN - D12.776.543.550.425.875.750.970.300 MN - D12.776.543.585.400.875.750.970.300 MN - D12.776.641.960.970.300 MS - A voltage-gated sodium channel beta subunit subtype that non-covalently associates with voltage-gated alpha subunits. Defects in the SCN3B gene which codes for this beta subunit are associated with Brugada syndrome 7. HN - 2013 FX - Brugada Syndrome MH - Voltage-Gated Sodium Channel beta-4 Subunit UI - D062585 MN - D12.776.157.530.400.875.750.960.650 MN - D12.776.543.550.425.875.750.970.400 MN - D12.776.543.585.400.875.750.970.650 MN - D12.776.641.960.970.650 MS - A voltage-gated sodium channel beta subunit subtype that covalently associates with voltage-gated alpha subunits. Defects in the SCN4B gene, which codes for this beta subunit, are associated with long QT syndrome-10. HN - 2013 FX - Long QT Syndrome MH - Voltage-Gated Sodium Channel Blockers UI - D061567 MN - D27.505.519.562.750.500 MN - D27.505.954.411.720.500 MS - A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. HN - 2013 MH - Voltage-Gated Sodium Channels UI - D061566 MN - D12.776.157.530.400.875.750 MN - D12.776.543.550.425.875.750 MN - D12.776.543.585.400.875.750 MN - D12.776.641.960 MS - A family of membrane proteins that selectively conduct SODIUM ions due to changes in the TRANSMEMBRANE POTENTIAL DIFFERENCE. They typically have a multimeric structure with a core alpha subunit that defines the sodium channel subtype and several beta subunits that modulate sodium channel activity. AN - general or unspecified; prefer specifics HN - 2013 MH - Waste Water UI - D062065 MN - D20.944.932 MN - N6.850.460.710.865 MS - Contaminated water generated as a waste product of human activity. HN - 2013 FX - Waste Disposal, Fluid MH - Water Resources UI - D062066 MN - G1.311.910 MS - Environmental reservoirs of water related to natural WATER CYCLE by which water is obtained for various purposes. This includes but is not limited to watersheds, aquifers and springs. HN - 2013 FX - Groundwater MH - Zonula Occludens Proteins UI - D062825 MN - D12.776.543.984.900 MS - A family of proteins that play a role in TIGHT JUNCTION formation by binding to and anchoring proteins to the ACTIN CYTOSKELETON. HN - 2013 BX - Zona Occludens Proteins MH - Zonula Occludens-1 Protein UI - D062826 MN - D12.776.543.984.900.500 MS - A 195-kDa zonula occludens protein that is distinguished by the presence of a ZU5 domain at the C-terminal of the molecule. HN - 2013 BX - Zona Occludens 1 Protein MH - Zonula Occludens-2 Protein UI - D062827 MN - D12.776.543.984.900.750 MS - A zonula occludens protein subtype found in epithelial cell junctions. Several isoforms of zonula occludens-2 protein exist due to use of alternative promoter regions and alternative mRNA splicings. HN - 2013 BX - Zona Occludens 2 Protein